Join
Live feed
·
PRReleasevia Quantisnow
MorphoSys AG logo

MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

ByQuantisnow·Wall Street's wire, on your screen.
MOR· MorphoSys AG
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MOR (MorphoSys AG) and more on Quantisnow.